Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06777589
Recruiting Not applicable

Quantitative Consciousness Index Monitoring (qNOX) of Sedation During Endoscopy

NCT06777589 · tracked via the Priya Life Science China tracker
Sponsor
Min Su
Phase
Not applicable
Started
2025-06-01
Last updated
2025-06-02

Condition(s) studied

Nociception

Investigational drug(s) / intervention(s)

Monitoring of anesthesia depth

Monitoring of anesthesia depth: During gastroscopy and colonoscopy procedures, the Bispectral Index Monitor (Apollo-9000A) is utilized to monitor patients' quantitative consciousness index (qCON) and quantitative nociception index (qNOX).

Study summary

Nociception is the encoding and processing of noxious stimulation and is considered an objective indicator for monitoring pain. Currently, a new clinically-applied medical-engineering integrated monitoring device for noxious stimulation response has emerged. Its fundamental principle is based on the monitoring of electroencephalographic (EEG) activity, incorporating two monitoring parameters: the quantitative consciousness (qCON) index and the quantitative nociceptive (qNOX) index. This device enables more precise monitoring of anesthesia depth, quantification of patients' anesthesia analgesia and stress levels, and reliable monitoring of responses to noxious stimulation. During tracheal intubation for general anesthesia, when the qCON value falls within the range of 40 to 60 and the qNOX value is between 30 and 50, it indicates that the patient is in an appropriate state of sedation and analgesia. However, there is currently no universally acknowledged standard for the optimal qNOX reference range during conscious sedation endoscopy. Therefore, this study utilizes the noxious stimulation response index (qNOX) to monitor noxious stimulation during the procedure, aiming to identify the best timing for inserting the endoscope during conscious sedation endoscopy and explore the appropriate range of qNOX for this purpose.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria 1. Age between 18 and 60 years old; 2. ASA-PS (American Society of Anesthesiologists Physical Status) classification of I to II; 3. Body Mass Index (BMI): 18 to 28 kg/m²; 4. Patients undergoing diagnostic and therapeutic procedures under sedation for lower gastrointestinal endoscopy; 5. Clear understanding and voluntary participation in this study, with informed consent signed. Exclusion Criteria 1. Patients requiring complex endoscopic techniques for diagnosis and treatment; 2. Patients who have participated in other clinical trials in the past three months; 3. Pregnant and lactating patients; 4. Patients with allergies to sedatives/anesthetics and other severe anesthesia risks; 5. Patients with preoperative chronic pain or a history of substance abuse; 6. Patients with severe neurological diseases such as stroke, hemiplegia, convulsions, epilepsy, etc.; 7. Patients with known difficult airways such as limited mouth opening, restricted neck and jaw movement, rheumatoid spondylitis, temporomandibular joint arthritis, etc.; 8. Patients with potentially life-threatening circulatory and respiratory diseases that are not adequately controlled, such as uncontrolled severe hypertension, severe arrhythmias, unstable angina pectoris, acute respiratory infections, asthma exacerbations, etc.; 9. Patients with liver dysfunction (Child-Pugh Class C or higher), acute upper gastrointestinal bleeding with shock, severe anemia, gastrointestinal obstruction with gastric retention.

Primary outcome measure(s)

  • The value of qNOX — Start of the procedure，when the gastroscope passes through the pharynx or the colonoscope passes through the anus.
    The value of qNOX when the gastroscope passes through the pharynx or the colonoscope passes through the anus.

Trial sites (1)

FacilityCityRegionStatus
China,Chongqing The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing Municipality Recruiting

More Min Su trials in China

Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study Recruiting
Anesthesia Induction Scheme for Painless Gastrointestinal Endoscopy Patients Based on Nociceptive Stimulation Monitoring Recruiting
Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke Recruiting

Other trials for the same condition

Anesthesia Induction Scheme for Painless Gastrointestinal Endoscopy Patients Based on Nociceptive Stimulation Monitoring Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06777589 on ClinicalTrials.gov ↗ ← All trials in China